Definition and research guide
This page combines a MeSH definition, publication statistics and selected research abstracts. It is a starting point for reading the literature, not a medical textbook or a systematic evidence review.
Content available: 4 complete abstracts (861 words), 10 references. Full article text is not stored or reproduced here; follow the PMID, DOI or PMC links to read the original sources and their access terms.
Definition
A specific protein in egg albumin that interacts with biotin to render it unavailable to mammals, thereby producing biotin deficiency.
Definition: NLM Medical Subject Headings (MeSH) scope note (Public domain (U.S. National Library of Medicine); attribution requested). View the MeSH record.
Where it fits in the MeSH classification
- Broader topics
- Glycoproteins; Ovalbumin
- See also
- Biotin
Related concepts
Research landscape
PubMed indexes 3,392 records tagged with the MeSH heading “Avidin” (counts retrieved 2026-10-31). 186 of them (5.5%) were published from 2020 onward, and the busiest period so far is through 1999 with 1,589 records.
Reviews account for 107 records (3.2%) and meta-analyses for 0. Randomized controlled trials number 5 (0.1%) as a share of all records on the topic. Randomized trials make up only a small share of this literature, so much of what is known comes from laboratory, observational or descriptive work.
Show the data
| Period | Records |
|---|---|
| through 1999 | 1,589 |
| 2000-2009 | 887 |
| 2010-2019 | 730 |
| 2020 onward | 186 |
Publication-type chart data
| Type | Records | Share |
|---|---|---|
| Reviews | 107 | 3.2% |
| Meta-analyses | 0 | 0.0% |
| Randomized controlled trials | 5 | 0.1% |
Method: PubMed query "Avidin"[MeSH Terms] with publication-type and date filters, retrieved 2026-10-31.
Reading the evidence in drugs and chemicals
Studies of a chemical or drug can answer very different questions: what it is and how it behaves in cells and animals, how the body handles it, and whether it changes outcomes in people. Laboratory and animal findings often do not carry over to patients, and observational studies of exposures are confounded by who uses a substance and why. Nothing on this page is a recommendation to use, avoid, start or stop any substance or medicine; talk to a qualified clinician or pharmacist about your own situation. Check the dose, the species, the comparison group and whether a patient-relevant outcome was measured.
Evidence from open-access studies
These open-access studies come from PubMed’s best-match results for this heading (papers whose main topic it is), ranked here by citation count, with one recent addition. Each abstract is reproduced in full under its recorded open licence so that you can read the authors’ own words. They illustrate the literature; they are not a systematic summary of it. Citation counts measure attention, not reliability or clinical benefit.
| Study / authors | Year | Source label / design | Europe PMC citations | Licence / source |
|---|---|---|---|---|
| Biochemical modifications of avidin improve pharmacokinetics and biodistribution, and reduce immunogenicity | 1998 | Research article Design not recorded in structured metadata | 86 | cc by PMID 9683292 · DOI · PMC2062912 |
| Detailed characterization of the solution kinetics and thermodynamics of biotin, biocytin and HABA binding to avidin and streptavidin | 2019 | Research article Design not recorded in structured metadata | 34 | cc by PMID 30818336 · DOI · PMC6394990 |
| Advanced surface passivation for high-sensitivity studies of biomolecular condensates | 2024 | Research article Design not recorded in structured metadata | 29 | cc by PMID 38781207 · DOI · PMC11145189 |
| Modular Assembly of Dynamic Polymer Networks From Heteroaffinity Cross-Links to Multivalent Proteins | 2026 | Research article Design not recorded in structured metadata | 0 | cc by PMID 41645662 · DOI · PMC13098475 |
Biochemical modifications of avidin improve pharmacokinetics and biodistribution, and reduce immunogenicity [1]
Abstract reading summary — source excerpts
- Opening excerpt
- Pretargeting techniques using the avidin-biotin system have shown encouraging results in both diagnostic and therapeutic clinical trials.
- Closing excerpt
- In conclusion, the conjugation of avidin to PEG chains (n = 7) originates a compound with a suitable blood clearance, low immunogenicity and concurrent low cross-reactivity with avidin.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (224 words)
Pretargeting techniques using the avidin-biotin system have shown encouraging results in both diagnostic and therapeutic clinical trials. It has been shown that in cancer therapy the ideal agent to be used for pretargeting should have a plasma half-life longer than avidin and lower immunogenicity than streptavidin in order for these procedures to be applied safely and repeatedly in patients. We prepared a recombinant form of avidin with no carbohydrates and avidins, biochemically modified either by decreasing the positive charges with succinic anhydride or by linking polyethylene glycol (PEG) at three different molar ratios and evaluated their in vivo behaviour after i.p. administration in mice. The succinylation and PEGylation of avidin increased the plasma half-life proportionally to the degree of protein modification. The procedures, however, affected the biotin binding to some extent. The biodistribution studies showed that, for all six time points (ranging from 20 min to 18 h post-injection), the liver and kidney to blood ratios were lower for PEGylated avidins than native, recombinant and succinyl avidin. Recombinant and low PEGylated avidin evoked an immune response in all mice after at least three injections. Native, recombinant and succinyl avidins showed higher serum titres than PEGylated avidins. In conclusion, the conjugation of avidin to PEG chains (n = 7) originates a compound with a suitable blood clearance, low immunogenicity and concurrent low cross-reactivity with avidin.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 9683292 · DOI · PMC2062912
Detailed characterization of the solution kinetics and thermodynamics of biotin, biocytin and HABA binding to avidin and streptavidin [2]
Abstract reading summary — source excerpts
- Opening excerpt
- The high affinity (KD ~ 10-15 M) of biotin for avidin and streptavidin is the essential component in a multitude of bioassays with many experiments using biotin modifications to invoke coupling.
- Closing excerpt
- Our new understanding and description of the kinetics, thermodynamics, and spectroscopic parameters for these complexes will help to improve purification efficiencies, molecule detection, and drug screening assays or find new applications.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (262 words)
The high affinity (KD ~ 10-15 M) of biotin for avidin and streptavidin is the essential component in a multitude of bioassays with many experiments using biotin modifications to invoke coupling. Equilibration times suggested for these assays assume that the association rate constant (kon) is approximately diffusion limited (109 M-1s-1) but recent single molecule and surface binding studies indicate that they are slower than expected (105 to 107 M-1s-1). In this study, we asked whether these reactions in solution are diffusion controlled, which reaction model and thermodynamic cycle describes the complex formation, and if there are any functional differences between avidin and streptavidin. We have studied the biotin association by two stopped-flow methodologies using labeled and unlabeled probes: I) fluorescent probes attached to biotin and biocytin; and II) unlabeled biotin and HABA, 2-(4'-hydroxyazobenzene)-benzoic acid. Both native avidin and streptavidin are homo-tetrameric and the association data show no cooperativity between the binding sites. The kon values of streptavidin are faster than avidin but slower than expected for a diffusion limited reaction in both complexes. Moreover, the Arrhenius plots of the kon values revealed strong temperature dependence with large activation energies (6-15 kcal/mol) that do not correspond to a diffusion limited process (3-4 kcal/mol). Accordingly, we propose a simple reaction model with a single transition state for non-immobilized reactants whose forward thermodynamic parameters complete the thermodynamic cycle, in agreement with previously reported studies. Our new understanding and description of the kinetics, thermodynamics, and spectroscopic parameters for these complexes will help to improve purification efficiencies, molecule detection, and drug screening assays or find new applications.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 30818336 · DOI · PMC6394990
Advanced surface passivation for high-sensitivity studies of biomolecular condensates [3]
Abstract reading summary — source excerpts
- Opening excerpt
- Biomolecular condensates are cellular compartments that concentrate biomolecules without an encapsulating membrane.
- Closing excerpt
- Our observations suggest a potential heterogeneity in the distribution of available polySIM-binding sites within the condensates.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (190 words)
Biomolecular condensates are cellular compartments that concentrate biomolecules without an encapsulating membrane. In recent years, significant advances have been made in the understanding of condensates through biochemical reconstitution and microscopic detection of these structures. Quantitative visualization and biochemical assays of biomolecular condensates rely on surface passivation to minimize background and artifacts due to condensate adhesion. However, the challenge of undesired interactions between condensates and glass surfaces, which can alter material properties and impair observational accuracy, remains a critical hurdle. Here, we introduce an efficient, broadly applicable, and simple passivation method employing self-assembly of the surfactant Pluronic F127 (PF127). The method greatly reduces nonspecific binding across a range of condensates systems for both phase-separated droplets and biomolecules in dilute phase. Additionally, by integrating PF127 passivation with the Biotin-NeutrAvidin system, we achieve controlled multipoint attachment of condensates to surfaces. This not only preserves condensate properties but also facilitates long-time fluorescence recovery after photobleaching imaging and high-precision single-molecule analyses. Using this method, we have explored the dynamics of polySIM molecules within polySUMO/polySIM condensates at the single-molecule level. Our observations suggest a potential heterogeneity in the distribution of available polySIM-binding sites within the condensates.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 38781207 · DOI · PMC11145189
Modular Assembly of Dynamic Polymer Networks From Heteroaffinity Cross-Links to Multivalent Proteins [4]
Abstract reading summary — source excerpts
- Opening excerpt
- Dynamic polymer networks (DPN) leverage transient cross-linking to yield macroscopic materials that exhibit self-healing and environmentally responsive behaviors.
- Closing excerpt
- We also develop a pH-sensitive HAX that yields DPNs with robust pH-responsive assembly dynamics, and demonstrate how this DPN can be made into a magnetically responsive, molecular delivery system to low-pH regions, such as tumor microenvironments.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (185 words)
Dynamic polymer networks (DPN) leverage transient cross-linking to yield macroscopic materials that exhibit self-healing and environmentally responsive behaviors. Despite the broad scope of chemical interactions available for cross-linking, imbuing those transient interactions into biologically compatible materials is difficult because many chemistries are incompatible with aqueous conditions, and it is difficult to tune preexisting biological interactions that have evolved over millions of years for specificity. To enable the assembly of chemically tunable and biologically compatible DPNs, we have developed a set of bifunctional, heteroaffinity cross-linkers (HAX) where the reactive moieties have different binding affinities to the same binding sites of an oligomeric protein. The use of cross-linking moieties with vastly different dissociation rates enables purification of protein modules with monodisperse HAX valencies. Assembly of DPNs from stoichiometrically identical pairs of protein modules then yields unique, metastable, nonequilibrium network topologies. Here, we demonstrate these concepts using the well-studied avidin-biotin interaction chemistry. We also develop a pH-sensitive HAX that yields DPNs with robust pH-responsive assembly dynamics, and demonstrate how this DPN can be made into a magnetically responsive, molecular delivery system to low-pH regions, such as tumor microenvironments.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 41645662 · DOI · PMC13098475
Key reviews and meta-analyses
The most cited review-type papers among PubMed’s best-match results for this heading, listed with bibliographic details only. Follow the links for the full text and access terms.
- Research article The avidin-biotin complex in bioanalytical applications [5]
- Research article The biotin-(strept)avidin system: principles and applications in biotechnology [6]
- Research article Introduction to avidin-biotin technology [7]
- Research article Genetically engineered avidins and streptavidins [8]
- Research article The principles and applications of avidin-based nanoparticles in drug delivery and diagnosis [9]
- Research article Avidin-biotin technology in targeted therapy [10]
References
- Chinol M, Casalini P, Maggiolo M, Canevari S, Omodeo ES, Caliceti P, et al.. Biochemical modifications of avidin improve pharmacokinetics and biodistribution, and reduce immunogenicity. . 1998. PMID 9683292 · DOI · PMC2062912
- Delgadillo RF, Mueser TC, Zaleta-Rivera K, Carnes KA, González-Valdez J, Parkhurst LJ. Detailed characterization of the solution kinetics and thermodynamics of biotin, biocytin and HABA binding to avidin and streptavidin. . 2019. PMID 30818336 · DOI · PMC6394990
- Yao RW, Rosen MK. Advanced surface passivation for high-sensitivity studies of biomolecular condensates. . 2024. PMID 38781207 · DOI · PMC11145189
- Dai T, Qiu Y, Leon Hernandez KM, Chan W, Mejia K, Nemeria N, et al.. Modular Assembly of Dynamic Polymer Networks From Heteroaffinity Cross-Links to Multivalent Proteins. . 2026. PMID 41645662 · DOI · PMC13098475
- Wilchek M, Bayer EA. The avidin-biotin complex in bioanalytical applications. Anal Biochem. 1988. PMID 3044183 · DOI
- Diamandis EP, Christopoulos TK. The biotin-(strept)avidin system: principles and applications in biotechnology. Clin Chem. 1991. PMID 2032315 · DOI
- Wilchek M, Bayer EA. Introduction to avidin-biotin technology. Methods Enzymol. 1990. PMID 2201884 · DOI
- Laitinen OH, Hytönen VP, Nordlund HR, Kulomaa MS. Genetically engineered avidins and streptavidins. Cell Mol Life Sci. 2006. PMID 17086379 · DOI · PMC11136427
- Jain A, Cheng K. The principles and applications of avidin-based nanoparticles in drug delivery and diagnosis. J Control Release. 2017. PMID 27865853 · DOI · PMC5222781
- Lesch HP, Kaikkonen MU, Pikkarainen JT, Ylä-Herttuala S. Avidin-biotin technology in targeted therapy. Expert Opin Drug Deliv. 2010. PMID 20233034 · DOI
About this article
- Sources
- NLM Medical Subject Headings (definition, synonyms); NCBI PubMed (counts, identifiers); Europe PMC (open-access abstracts and citation counts).
- Verification
- Every reference was resolved against PubMed on 2026-10-31; title, year and DOI matched.
- Review state
- automated source verified; no human expert review has been recorded yet.
- Version
- 1, last updated 2026-10-31.
See how EvidenceLib is built. Spotted an error? Email support@evidencehelix.com.
Evidence strength
EvidenceHelix's computed view of the study designs behind this topic: how common meta-analyses, randomized trials and reviews are, how recent the literature is, and a plain-language reading. It describes the design mix of the literature. It is not a quality appraisal of any study, and it is not medical advice.